[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]

[[ timeLabel ]] WATCH LIVE:

Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

Faster, Cleaner, Better.

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Relmada Therapeutics Inc (RLMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Relmada Reports Tomorrow on a Pipeline That Exists Entirely in the Conditional Tense Barchart - Mon May 11, 4:07PM CDT

Barchart Research What to Expect from RLMD Earnings RLMD Generated May 11, 2026 Current Price $7.36 EPS Estimate $$-0.18 Consensus Rating Strong Buy Average Move 5.00% Relmada Reports Tomorrow on a Pipeline...

Bullish - green stock market chart with arrow up day trade by Quality Stock Arts via Shutterstock

This Stock Is Up 704% in 2025 But Has No Products to Its Name Barchart - Thu Nov 20, 2025

Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap. RLMD has shown strong technical momentum, gaining 440% since August. Shares...

Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives Quiver Quantitative, Inc. - Mon Dec 9, 2024

Relmada Therapeutics discontinues Phase 3 studies and explores strategic alternatives to enhance shareholder value.Quiver AI SummaryRelmada Therapeutics, Inc., a biotechnology company focused on central...

Relmada Therapeutics Initiates Phase 1 Study of REL-P11, a Low-Dose Psilocybin Formulation for Metabolic Disease Quiver Quantitative, Inc. - Thu Nov 14, 2024

Relmada initiates Phase 1 study for REL-P11, a psilocybin formulation for metabolic disorders, with Phase 2a planned for 2025.Quiver AI SummaryRelmada Therapeutics has announced the initiation of dosing...

Healthcare - COVID-19 vaccines by HakanGERMAN via Pixabay

2 Breakout Biotech Stocks With CEO Insider Buying Barchart - Tue Sep 17, 2024

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 PR Newswire - Wed Oct 11, 2023